The impact of a three-tier formulary on demand response for prescription drugs

Journal of Economics and Management Strategy

Volumn 14, Issue 3, 2005, Pages 729-753

  Huskamp, Haiden A ^a   Frank, Richard G ^b   Mcguigan, Kimberly A ^c   Zhang, Yuting ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

^c PFIZER INC   (United States)

^d HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 24144453538     PISSN: 10586407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1530-9134.2005.00080.x     Document Type: Article

References (49)

1. Ai, C. and B.C. Norton, 2003, "Interaction Terms in Logit and Probit Models," Economics Letters, 80, 123-129.
2. Berndt, E.R., 2003, "Pharmaceuticals in US Health Care: Determinants of Quantity and Price," Journal of Economic Perspectives, 16(4), 45-66.
3. Brian, E.W. and S.F. Gibbens, 1974, "California's Medical Co-payment Experiment," Medical Care, 12(12 suppl), 1-56.
4. Centers for Medicare and Medicaid Services (CMS), "The Nation's Health Dollar, 2001," available at http://cms.hhs.gov/statistics/nhe/ historical/chart.asp.
5. D'Agostino, R.B., 1998, "Propensity Score Methods for Bias Reduction in the Comparison of Treatment to a Nonrandomized Control Group," Statistics in Medicine, 17, 2265-2281.
6. Domino, M.E. and D.S. Salkever, 2002, "Price Elasticity and Pharmaceutical Selection: The Influence of Managed Care," Health Economics, 12, 565-586.
7. Dranove, D., 1989, "Medicaid Drug Formulary Restrictions," Journal of Law and Economics, 32(1), 143-162.
8. Duan, N., 1983, "Smearing Estimate: A Nonparametric Retransformation Method," Journal of the American Statistical Association, 78, 605-610.
9. Duan, N., W.G. Manning, C.N. Morris, and J. P. Newhouse, 1983, "A Comparison of Alternative Models for the Demand for Medical Care," Journal of Business and Economic Statistics, (2), 115-126.
10. Ellison, S.F., I. Cockburn, Z. Griliches, and J. Hausman, 1997, "Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins," RAND Journal of Economics, 28(3), 426-446.
11. Frank, R.G., 2001, "Prescription Drug Prices: Why Do Some Pay More Than Others Do?" Health Affairs, 20(2), 115-128.
12. Goldman, D.P., G.F. Joyce and J. J. Escarce et al, 2004, "Pharmacy Benefits and the Use of Drugs by the Chronically 111," Journal of the American Medical Association, 291, 2344-2350.
13. Hillman, A., M.V. Pauly, J. J. Escarce, K. Ripley, M. Gaynor, J. Clouse, and R. Ross, 1999, "Financial Incentives and Drug Spending in Managed Care," Health Affairs, 18(2), 189-200.
14. Horn, S.D., P.D. Sharkey, and C. Phillips-Harris, 1998, "Formulary Limitations and the Elderly: Results From the Managed Care Outcomes Project," American Journal of Managed Care, 1105-1113.
15. Huber, P.J., 1967, "The Behavior of Maximum Likelihood Estimates under Nonstandard Conditions," In Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability. Berkeley, CA: University of California Press, 1, 221-233.
16. Huskamp, H.A., P.A. Deverka, A.M. Epstein, R.S. Epstein, K.A. McGuigan, and R.G. Frank, 2003, "The Effect of Incentive-Based Formularies on Prescription-Drug Utilization and Spending," New England Journal of Medicine, 349, 2224-2232.
17. _, M.B. Rosenthal, R.G. Frank, and J.P. Newhouse, 2000, "The Medicare Prescription Drug Benefit: How Will the Game Be Played," Health Affairs, 19(2), 8-23.
18. Kamal-Bahl, S. and B. Briesacher, 2004, "How Do Incentive-based Formularies Influence Drug Selection and Spending for Hypertension?" Health Affairs, 23(1), 227-236.
19. Levy, R. and D. Cocks, 1999, "Component Management Fails to Save Health Care Systems Costs: The Case of Restrictive Formularies," second edition, National Pharmaceutical Council.
20. Joyce, G.F., J.J. Escarce, M.D. Solomon, and D.P. Goldman, 2002, "Employer Drug Benefit Plans and Spending on Prescription Drugs," Journal of the American Medical Association, 288(14), 1733-1774.
21. Kaiser Family Foundation and the Health Research and Educational Trust, 2004, "Employer Health Benefits, 2004 Annual Survey," http://www.kff.org/insurance/7148/index.cfm [accessed on June 6, 2005].
22. Kamal-Bahl, S. and B. Briesacher, 2004, "How Do Incentive-based Formularies Influence Drug Selection and Spending for Hypertension?" Health Affairs, 23(1), 227-236.
23. Keeler, E.B. et al, 1986, The Demand for Episodes of Mental Health Services, RAND.
24. Liebowitz, A., W.G. Manning, and J.P. Newhouse, 1985, "The Demand For Prescription Drugs as a Function of Cost-Sharing," Social Science and Medicine, 21, 251-277.
25. Ma, C.A. and T.G. McGuire, 2002, "Network Incentives in Managed Health Care," Journal of Economics and Management Strategy, II(1), 1-35.
26. Manning, W.G., J.P. Newhouse, N. Duan, E. B. Keeler, A. Leibowitz, and M.S. Marquis, 1987, "Health Insurance and the Demand for Medical Care: Evidence from a Randomized Experiment," American Economic Review, 77, 251-277.
27. _, 1998, "The Logged Dependent Variable, Heteroskedasticity and the Retransformation Problem," Journal of Health Economics, 17, 247-281.
28. Manning, W.G., A. Basu, and J. Mullahy, 2003, "Modeling Costs with Generalized Gamma Regression," working paper.
29. _ and J. Mullahy, 2001, "Estimating Log Models: To Transform or Not to Transform," Journal of Health Economics, 20, 461-494, (March 2001).
30. _ and M.S. Marquis, 1996, "Health Insurance: The Tradeoff Between Risk Pooling and Moral Hazard," Journal of Health Economics, 15(5), 609-639.
31. Moore, W.J. and R.J. Newman, 1993, "Drug Formulary Restrictions as a Cost-Containment Policy in Medicaid Programs," Journal of Law and Economics, XXXVI, 71-97.
32. Morton, F.S., 1997, "The Strategic Response by Pharmaceutical Firms in the Medicaid Most-Favored-Customer Rules," RAND Journal of Economics, 28(2), 269-290.
33. Motheral, B.R. and K.A. Fairman, 2001, "Effect of a Three-Tier Prescription Co-pay on Pharmaceutical and Other Medical Utilization," Medical Care, 39(12), 1293-1304.
34. Novartis, 2001, Pharmacy Benefit Report: Facts and Figures.
35. Rector, T.S., M.D. Finch, P.M. Danzon, M.V. Pauly, and B. S. Manda, 2003, "Effect of Tiered Prescription Co-payments on the Use of Preferred Brand Medications," Medical Care, 41(3), 398-406.
36. Reeder, C. and A. Nelson, 1985, "The Differential Impact of Co-payment on Drug Use in a Medicaid Population," Inquiry, 22, 396-403.
37. Rosenthal, M.B., E.R. Berndt, J.M. Donohue, R.G. Frank, and A.M. Epstein, 2002, "Promotion of Prescription Drugs to Consumers," New England Journal of Medicine, 346(7), 498-505.
38. Scherer, F.M., 2000, "The Pharmaceutical Industry," in Handbook of Health Economics, volume 1B, A.J. Culyer and J.P. Newhouse, eds., New York: Elsevier.
39. Schweitzer, S.O., 1997, Pharmaceutical Economics and Policy, New York: Oxford University Press.
40. Sloan, F.A., G.S. Gordon, and D.L. Cocks, 1993, "Hospital-Drug Formularies and Use of Hospital Services," Medical Care, 31(10), 851-867.
41. Smith, M. and D. Garner, 1974, "Effects of a Medicaid Program on Prescription-Drug Availability and Acquisition," Medical Care, 571-581.
42. Soumerai, S.B., J. Avorn, D. Ross-Degnan, and S. Gortmaker, 1987, "Payment Restrictions for Prescription Drugs under Medicaid: Effects on Therapy, Cost and Equity," New England Journal of Medicine, 317(9), 550-556.
43. Tamblyn, R.T., R. Laprise, J.A. Hanley, M. Abrahamowicz, S. Scott, N. Mayo, J. Hurley, R. Grad, E. Latimer, R. Perreault, P. McLeod, A. Huang, P. Larochelle, and L. Mallet, 2001, "Adverse Events Associated with Prescription Drug Cost-Sharing among Poor and Elderly Persons," Journal of the American Medical Association, 285(4), 421-429.
44. Task Force on Prescription Drugs, US Department of Health, Education and Welfare, 1968, "The Drug Makers and the Drug Distributors," Washington DC.
45. Tirole, J., 1992, The Theory of Industrial Organization, Cambridge, Massachusetts: MIT Press.
46. United States General Accounting Office, 2003, Federal Employees' Health Benefits: Effects of Using Pharmacy Benefit Managers on Health Plans, Enrollees, and Pharmacies, GAO-03-196, Washington DC: Author.
47. Viscusi, W.K., J.M. Vernon, and J. E. Harrington, 2000, Economics of Regulation and Antitrust, Cambridge, MA: MIT Press.
48. White, H., 1980, "A Heteroskedasticity-consistent Covariance Matrix Estimator and a Direct Test for Heteroskedasticity," Econometrica, 48(4), 817-830.
49. Wolfe, M.M., 2003, "Overview and Comparison of the Proton-Pump Inhibitors for the Treatment of Acid-related Disorders," availalable at www.uptodate.com, search on "proton pump inhibitors" [accessed on April 24, 2003].